Incyte to Acquire Vega Therapeutics for up to $2.0 Billion, Expanding Hematology Portfolio

Incyte Corporation announced a definitive agreement to acquire Vega Therapeutics, Inc., a subsidiary of Star Therapeutics, for an upfront payment of $1.25 billion. The acquisition expands Incyte's hematology portfolio with a late-stage asset for bleeding disorders, with the total potential deal value reaching up to $2.0 billion.

Key Details

• Acquisition Terms: Incyte will pay $1.25 billion upfront, with up to an additional $750 million in payments contingent on achieving certain sales milestones.
• Strategic Asset: The acquisition adds VGA039, a novel monoclonal antibody in Phase 3 development for the treatment of von Willebrand disease (VWD), the most common inherited bleeding disorder.
• Timeline & Financial Impact: The transaction is expected to close in the third quarter of 2026 and will result in an approximate $1.25 billion R&D charge for Incyte in Q3 2026.